CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$55.24 USD
-0.49 (-0.88%)
Updated May 24, 2024 04:00 PM ET
After-Market: $55.75 +0.51 (0.92%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Brokerage Reports
0 items in cart
CRISPR Therapeutics AG [CRSP]
Reports for Purchase
Showing records 61 - 80 ( 209 total )
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
1Q22: Getting Closer to Commercializing its First Asset
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
AACR 2022 Abstract Titles Released: BCYC CRSP GTBP PBLA TCRR
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Hemoglobinopathy Program Regulatory Submission, Oncology Data in 2022
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Looking into 1Q22, Cash Balance, & Price Target Changes
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Biotechnology-Looking into 1Q22, Cash Balance, & Price Target Changes
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
First Patient Treated For Diabetes With Gene-edited Cells
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department